Chemokines and matrix metalloproteinases in cerebrospinal fluid of patients with central nervous system complications caused by varicella-zoster virus

Table 1 Clinical data of patients with VZV CNS infections and controls (median and range)

	Encephalitis	Meningitis	Ramsay Hunt	Controls
Patients no.	29	21	17	24
Age	75 (29–88)	30 (15–84)	60 (13–82)	38 (17–76)
F/M	10/18	9/12	6/11	10/14
CSF VZV DNA copies/ml	17,000 (70–25 millions)	15,100 (50–224,000)	950 (50–759,000)	NA
Intravenous treatment¹ (days) (no.)	11 (0–18) (no. 27)	2 (1–10) (no. 14)	8 (2–14) (no. 10)	NA
Oral treatment² only (days) (no.)	(no. 2)	7 (7–7) (no. 6)	7 (7–14) (no. 8)	NA

VZV varicella-zoster virus, CNS central nervous system, CSF cerebrospinal fluid, NA not analyzed, t.i.d three times/day
¹Dosage of i.v acyclovir was 10–15 mg/kg t.i.d, except for patients with renal failure. Additionally, oral treatment to the i.v treatment was given to 23 patients with VZV CNS infections with valacyclovir 1 g t.i.d or acyclovir 800 mg five times a day
²Oral treatment was given as valacyclovir 1 g t.i.d

ISSN: 1742-2094